Big data and artificial intelligence (AI) can significantly accelerate many processes and make them more efficient. The Paris, France-based start-up Iktos is developing a proprietary AI technology for ligand and structure-based de novo drug design, focusing on multi parametric optimization (MPO). Yann Gaston-Mathé, co-founder and CEO of Iktos, explains the company’s technologies and provides an outlook on the further development of the company. Read the full article here.
